Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Genentech chemistry leadership shifts

by Lisa M. Jarvis
January 1, 2018 | A version of this story appeared in Volume 96, Issue 1

Young
[+]Enlarge
Credit: Genentech
A photo of Genentech's Wendy Young.
Credit: Genentech

Medicinal chemist Wendy Young has been promoted to senior vice president for small-molecule drug discovery at Genentech. Young previously led a team of roughly 100 medicinal, computational, and analytical chemists; she will now run the 350-scientist small-molecule research engine for Genentech, a subsidiary of Roche. Young is taking over the reins from medicinal chemist Bruce Roth, who is retiring. Roth, known for being the first to synthesize atorvastatin—better known as Pfizer’s multi-billion-dollar cholesterol-lowering drug Lipitor, joined Genentech in 2007, after Pfizer laid off thousands of scientists at its Ann Arbor, Mich., site.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.